- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 35/02 - Antineoplastic agents specific for leukemia
Patent holdings for IPC class A61P 35/02
Total number of patents in this class: 8353
10-year publication summary
285
|
289
|
330
|
616
|
746
|
888
|
941
|
996
|
807
|
239
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Novartis AG | 11238 |
144 |
Immatics Biotechnologies GmbH | 1144 |
99 |
Dana-Farber Cancer Institute, Inc. | 2455 |
79 |
Daiichi Sankyo Company, Limited | 1829 |
76 |
Celgene Corporation | 1412 |
74 |
Toray Industries, Inc. | 6652 |
72 |
Memorial Sloan-Kettering Cancer Center | 1789 |
64 |
Genentech, Inc. | 3742 |
59 |
The Regents of the University of California | 18943 |
58 |
Takeda Pharmaceutical Company Limited | 2961 |
57 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
49 |
Board of Regents, The University of Texas System | 5370 |
47 |
Janssen Pharmaceutica N.V. | 3839 |
46 |
F. Hoffmann-La Roche AG | 7958 |
43 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 762 |
40 |
Janssen Biotech, Inc. | 1347 |
39 |
The General Hospital Corporation | 4517 |
34 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
34 |
Centre National de La Recherche Scientifique | 9632 |
33 |
FUJIFILM Corporation | 27102 |
33 |
Other owners | 7173 |